LINDSAY WOOD: Open Payments
NPI 1609484609 · CLERMONT, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,167 in 55 payments from 17 companies in 2025. Trend: 2023 $1,588 · 2024 $1,663 · 2025 $1,167
Food & beverage: $1,167
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 13 | $360 |
| Novo Nordisk Inc | 11 | $153 |
| Amgen Inc. | 5 | $88 |
| Sumitomo Pharma America, Inc. | 3 | $76 |
| GlaxoSmithKline, LLC. | 3 | $75 |
| PFIZER INC. | 3 | $60 |
| Astellas Pharma US Inc | 2 | $53 |
| Otsuka America Pharmaceutical, Inc. | 2 | $48 |
| ABBVIE INC. | 2 | $42 |
| SHIELD THERAPEUTICS INC | 2 | $39 |
Products named: FARXIGA, Ozempic, AIRSUPRA, GEMTESA, TRELEGY ELLIPTA, OTEZLA, Veozah, REXULTI.
Industry payments across FL — which companies pay providers there.
